Top Markets
Coin of the day
Laboratorios Farmaceuticos Rovi, S.A. Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A.

ROVI
Ранг среди акций #4452
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses... Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
Цена акции
$72.12
Рыночная капитализация
$3.69B
Изменение (1 день)
0.50%
Изменение (1 год)
8.29%
Страна
ES
Торговля Laboratorios Farmaceuticos Rovi, S.A. (ROVI)

Категория

Операционная маржа для Laboratorios Farmaceuticos Rovi, S.A. (ROVI)
Операционная маржа на 2026 TTM: 0.00%
Согласно последним финансовым отчетам и цене акций Laboratorios Farmaceuticos Rovi, S.A., текущая операционная маржа (TTM) составляет 0.00%. В конце 2026 она составила 0.00%.
История операционной маржи Laboratorios Farmaceuticos Rovi, S.A. с 2026 по 2026
Операционная маржа на конец каждого года
Год Операционная маржа Изменить
Недостаточно данных для указанных дат.
Операционная маржа для аналогичных компаний или конкурентов
Компания Операционная маржа Разница в операционной марже Страна
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
22.93% -
IN
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.